Clinical cases of eculizumab use as a part of complex therapy in patients with severe COVID-19.

2021 ◽  
Author(s):  
Р.А. Майер ◽  
Б.А. Бакиров ◽  
А.А. Набиева ◽  
Д.А. Кудлай
Keyword(s):  
Virus Disease ◽  
Membrane Attack Complex ◽  
Lung Ventilation ◽  
Blood Analysis ◽  
The Novel ◽  
Reactive Protein ◽  
Corona Virus ◽  
Complex Therapy ◽  
Novel Coronavirus ◽  
Clinical Cases

Введение. В последние 2 года серьезной проблемой для всего мирового сообщества стало распространение новой коронавирусной (CoV) инфекции COVID-19 (COrona VIrus Disease-2019). Ввиду сложившихся событий в лечении COVID-19 активно стали применяться новые молекулы и уже зарегистрированные лекарственные препараты, доказавшие свою эффективность при других заболеваниях. Цель исследования: оценить эффективность применения препарата экулизумаб у пациентов с тяжелой формой течения COVID-19. Материалы и методы. Проанализированы 3 клинических случая применения препарата экулизумаб в составе комплексной терапии у пациентов с тяжелой формой течения COVID-19. Для оценки эффективности лечения проводился мониторинг основных клинико-лабораторных показателей, а также показателей, характеризующих воспалительный процесс при коронавирусной инфекции: общий анализ крови, биохимический анализ крови, проанализированы уровни таких показателей как ферритин, С-реактивный белок, интерлейкин-6, лактатдегидрогеназа и мембраноатакующий комплекс. Результаты. На фоне проводимой терапии выявлено снижение концентрации основных маркеров воспаления относительно исходных значений. Заключение. Комплексная терапия, включающая экулизумаб, облегчает течение заболевания, позволяет сократить длительность пребывания пациентов в отделении реанимации и интенсивной терапии, укорачивает срок их пребывания на искусственной вентиляции легких, тем самым снижая процент летальности. Background. In the past two years, the incidence of the novel coronavirus (CoV) infection COVID-19 (COrona Virus Disease-2019) has been a serious problem for the global community. Considering these circumstances, new molecules and already registered drugs that have proven their effectiveness in other diseases, began to be actively used in COVID-19 treatment. Objectives: to assess the effi cacy of eculizumab in patients with severe COVID-19. Patients/Methods. Three clinical cases of eculizumab use as a part of complex therapy in patients with severe COVID-19 have been analyzed. To assess the treatment efficacy, the main clinical and laboratory parameters and indicators of inflammatory process in coronavirus infection were monitored (clinical blood analysis, biochemical blood test, levels of ferritin, C-reactive protein, interleukin-6, lactate dehydrogenase and membrane attack complex). Results. Under the therapy we found the reduction of concentration of the main inflammation markers relative to the initial values. Conclusions. Complex therapy with eculizumab facilitates the course of the disease, reduces the stay duration of patients in the intensive care unit, shortens the period of artificial lung ventilation, thereby reducing the mortality rate.

scholarly journals The First Case of Reactive Arthritis Associated with SARS-CoV-2-Infection in A 4-Year Old Child

2020 ◽  
Author(s):  
Stephanie Gabriele Werner ◽  
Hans-Eckhard Langer
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Reactive Arthritis ◽  
Virus Disease ◽  
The Novel ◽  
Case Presentation ◽  
Corona Virus ◽  
First Case ◽  
Novel Coronavirus ◽  
The Right

Abstract Background: The novel coronavirus SARS‐CoV‐2 (severe acute respiratory syndrome coronavirus 2) and its associated disease COVID‐19 (Corona Virus Disease 19) has become a worldwide pandemic since its first cases in December 2019 in Wuhan Province in China. In Germany the pandemic started in February 2020.Case presentation: A 4 year old boy was presented and suffered from pain in the right hip. Arthrosonography demonstrated a significant effusion in the involved joint. The extended history revealed a slight but long lasting cold before. Serological findings were inconspicuous except for positive ELISA (Enzyme-linked Immuno Sorbent Assay) - test for SARS-CoV-2. Conclusion: In conclusion we believe that we can report the first case of reactive arthritis associated with SARS-CoV-2 in children.

The novel coronavirus and its possible treatment by vaccines, therapeutics and drug delivery systems: Current status and future perspectives

2020 ◽  
Vol 11 (SPL1) ◽  
pp. 54-61 ◽  
Author(s):  
Madhurya Kadavakollu ◽  
Veera Venkata Satyanarayana Reddy Karri ◽  
Kuppusamy Gowthamarajan ◽  
Arun Radhakrishnan ◽  
Dhanabal Palanisamy ◽  
...  
Keyword(s):  
Virus Disease ◽  
World Health ◽  
Current Status ◽  
The Novel ◽  
Future Perspectives ◽  
Epidemic Disease ◽  
Wuhan City ◽  
Corona Virus ◽  
Novel Coronavirus ◽  
Health Organization

In the mid-end of December 2019, several cases of pneumonia outbreak of unknown cause and etiology were identified in Wuhan City of Hubei province in China, a city with a population of over 11 million.Till date(April 2020) around 1,051,635 confirmed cases of coronavirus disease 2019(COVID-19) and 56,985 confirmed deaths have been reported according to COVID-19 Situation Report – 75 by WHO. On 7th January 2020, the causative agent was identified and named consequently as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) by the Chinese Centre for Disease Control and Prevention (CCDC) from throat swab samples. Later, on 12th January 2020, this coronavirus was named as 2019-novel coronavirus (2019-nCoV) by World Health Organization (WHO) and in 11th February 2020,it has been declared the epidemic disease caused by SARS-CoV-2 as Corona Virus Disease 2019(COVID-19) as it is spreading rapidly from its origin in Wuhan City to the rest of the world. In this context, the current review provides a landscape of the novel Corona Virus including its origin, transmission, epidemiology, drugs and vaccines in clinical trials for better understanding to the reads and peoples the status and future perspectives of this pandemic disease

scholarly journals SARS-CoV-2 - Understanding for the Preparation of Forthcoming Corona Virus Outbursts

2020 ◽  
pp. 46-55
Keyword(s):  
Virus Disease ◽  
Deep Understanding ◽  
Disease Outbreak ◽  
International Committee ◽  
Technological Advance ◽  
The Novel ◽  
Corona Virus ◽  
The World ◽  
Novel Coronavirus

A new major epidemic foci of corona virus disease 2019 known as COVID-19, previously known as 2019-nCoV have been identified and rapidly expanding throughout the world without traceable origin since early 2020. The disease has drastically increased and the affected number of countries, states or territories reporting infection to WHO was more than 2001. The 2019 novel corona virus disease outbreak was instigated from Wuhan, Hubei province, China at late December 2019 and affirmed as a public health threat emerging of International anxiety on 30th January 2020 by WHO2. International Committee on Taxonomy of Viruses (ICTV) declared “Severe Acute Respiratory Syndrome Corona Virus (SARS-CoV2)” as the name of novel corona virus, because their genetically similarities with SARS outbreak in 2003. The present review focuses on morphological, genetical characterization of SARS – CoV – 2 as well as the clinical traits and clinical therapies for COVID – 19 endemic up to date. The novel coronavirus emergence awaken the echoes of SARS-CoV pandemic in past decades. Yet, with having best technological advance, the exact medication is still a question. It might be a great lesson to the world to equip to deal with most recent emergent viruses in future. The current work will give a deep understanding of CoV -2 to researcher for the further studies.

scholarly journals Retrospective analysis of the clinical features of outpatients with novel coronavirus in areas outside Wuhan, China

2020 ◽  
Author(s):  
Yong-Tao Li ◽  
Mei-Lian Peng ◽  
Jia-dan Fu ◽  
Li Liu ◽  
Yong-zheng Guo ◽  
...  
Keyword(s):  
Pathogen Detection ◽  
Clinical Performance ◽  
The Novel ◽  
C Reactive Protein ◽  
Early Screening ◽  
Reactive Protein ◽  
Ct Findings ◽  
Epidemic Area ◽  
Novel Coronavirus ◽  
Lung Ct

Abstract Objective: The novel coronavirus pneumonia (COVID-19) has spread rapidly across the globe with the movement of people. How to diagnose COVID-19 quickly and accurately is a concern for all. We retrospectively assessed the clinical characteristics of patients with COVID-19 detected by outpatient screening in areas outside Wuhan, China, to guide early screening outside the epidemic area, to isolate and treat COVID-19-positive patients, and to control the spread of this virus in the region.Results: Among the 213 patients treated in the fever clinic of our hospital, 41 tested positive for novel coronavirus (2019-nCoV) and 172 were negative. Among the positive patients, 13 (31.7%) of the patients had been to Wuhan, while 28 (68.3%) had not been to Wuhan. There were 4 cases of clustering occurrence. The main symptoms exhibited by COVID-19-positive patients were fever (87.8%), cough (68.3%), and expectoration (34.1%). The C-reactive protein (CRP) levels were increased in 35 (85.3%) positive patients; the hydroxybutyrate dehydrogenase in the myocardial zymogram was increased in 22 positive patients (53.6%) and 38 negative patients (22.1%); computed tomography (CT) findings revealed lung lesions in all 41 positive patients (100%).Conclusion: We classified the patient population and analyzed the data to understand the early clinical performance of COVID-19. Our research illustrate that screening for COVID-19 outside Wuhan should focus on early symptoms such as fever and cough, in combination with lung CT findings, epidemiological history, and sputum pathogen detection to determine whether patients need further isolation.

scholarly journals Clinical and Laboratory Profiles of 75 Hospitalized Patients with Novel Coronavirus Disease 2019 in Hefei, China

2020 ◽  
Author(s):  
Zonghao Zhao ◽  
Jiajia Xie ◽  
Ming Yin ◽  
Yun Yang ◽  
Hongliang He ◽  
...  
Keyword(s):  
T Cell ◽  
Treatment Effectiveness ◽  
Antiviral Treatment ◽  
Laboratory Data ◽  
Clinical Manifestations ◽  
Nasopharyngeal Swab ◽  
The Novel ◽  
Reactive Protein ◽  
Cell Counts ◽  
Novel Coronavirus

AbstractThe outbreak of the novel coronavirus disease 2019 (COVID-19) infection began in December 2019 in Wuhan, and rapidly spread to many provinces in China. The number of cases has increased markedly in Anhui, but information on the clinical characteristics of patients is limited. We reported 75 patients with COVID-19 in the First Affiliated Hospital of USTC from Jan 21 to Feb 16, 2020, Hefei, Anhui Province, China. COVID-19 infection was confirmed by real-time RT-PCR of respiratory nasopharyngeal swab samples. Epidemiological, clinical and laboratory data were collected and analyzed. Of the 75 patients with COVID-19, 61 (81.33%) had a direct or indirect exposure history to Wuhan. Common symptoms at onset included fever (66 [88.0%] of 75 patients) and dry cough (62 [82.67%]). Of the patients without fever, cough could be the only or primary symptom. The most prominent laboratory abnormalities were lymphopenia, decreased percentage of lymphocytes (LYM%), decreased CD4+ and CD8+ T cell counts, elevated C-reactive protein (CRP) and lactate dehydrogenase (LDH). Patients with elevated interleukin 6 (IL-6) showed significant decreases in the LYM%, CD4+ and CD8+ T cell counts. Besides, the percentage of neutrophils, CRP, LDH and Procalcitonin levels increased significantly. We concluded that COVID-19 could cause different degrees of hematological abnormalities and damage of internal organs. Hematological profiles including LYM, LDH, CRP and IL-6 could be indicators of diseases severity and evaluation of treatment effectiveness. Antiviral treatment requires a comprehensive and supportive approach. Further targeted therapy should be determined based on individual clinical manifestations and laboratory indicators.

scholarly journals The impact of COVID-19 pandemic on the treatment of acute appendicitis in China

2021 ◽  
Author(s):  
ZhiXue Zheng ◽  
Jing Tao Bi ◽  
Ya Qi Liu ◽  
Xuan Cai
Keyword(s):  
Acute Appendicitis ◽  
White Blood Cells ◽  
Onset Time ◽  
The Novel ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Number Of Patients ◽  
Hospital Visits ◽  
Novel Coronavirus ◽  
The Impact

Abstract Objective This research aims to analyze the impact of the novel coronavirus pandemic on the hospital visits of patients with acute appendicitis. Methods The retrospective analysis was designed to look at the treatment of acute appendicitis in the Department of General Surgery in Beijing Jishuitan Hospital before and during the COVID-19 pandemic (2019–2020). Data was analyzed by the numbers of patients, sex, age, onset time, fever or not, laboratory examination, imaging test, and treatment. And we analyzed the differences between the “pre-COVID group” and “during-COVID group”. Results Compared with the year 2019, the number of acute appendicitis patients has diminished substantially during the COVID-19 pandemic (2020), but the number elevated with the control of the pandemic. Even if we did not find the differences of the treatment before and during the pandemic (P = 0.932), the onset time to emergency was significantly longer (P < 0.001), and more patients had showed fever (P < 0.001) during the COVID-19 pandemic. And the total number of white blood cells and C reactive protein level were significantly higher in 2020 than those in 2019 (P = 0.006, 0.003). And the same result was found in patients with appendiceal fecalith (P = 0.047). Conclusion During the pandemic of the new coronavirus pneumonia, the number of patients with acute appendix treatment dropped significantly, mainly because it took longer than before, and the condition was more severe. It can be seen that the new coronary pneumonia has a great impact on the patients’ medical treatment behavior, and the active prevention and treatment of the new coronavirus pneumonia is currently an important and urgent issue.

Psychosocial Effects and Panic Regarding Corona Virus

2020 ◽  
Vol 11 (SPL1) ◽  
pp. 1689-1694
Author(s):  
Amir Ali
Keyword(s):  
Virus Disease ◽  
Medical Services ◽  
Way Of Life ◽  
Psychosocial Effects ◽  
Web Based ◽  
Corona Virus ◽  
Economic Weight ◽  
The World ◽  
Novel Coronavirus

After the hike of the Coronavirus from the country of China in the end of the previous year, Novel Coronavirus accounts for a total of about 46 million cases all around the world with the death of more than 1.28 million individuals & 31.8 million recoveries. Besides its extraordinary infectivity & casualty rates, Corona Virus Disease has caused widespread panic, economic weight & budgetary misfortunes. Mass terror of CORONA VIRUS, named as "corona phobia", has made an adequate mental indications in over-all population. Along these lines, this audit has been embraced to characterize panic consequence of CORONA Virus. The quarantine can create extreme anger, nervousness, accumulating, psychological illness & sadness. Strengthened through an "infodemic" extent through a various foundation in web-based broadcasting. Upheavals bigotry, defamation, & tolerance against specific networks remain additionally being broadly detailed. All things considered, bleeding-edge medical services laborers are at higher danger of getting the illness just as encountering unfriendly mental results in a type of burnout, tension, fear of communicating contamination, a sentiment of contrariness, wretchedness, & extended substance-reliance. Network-based alleviation projects to battle coronavirus will upset youngster normal way of life & may cause flowery psychological depression. Networks remain pretentious by disease in several manners & want exceptional consideration. 

scholarly journals Role of Notary in Capital Market: Making GMS Minutes Online During Covid-19

Jurnal Akta ◽  
2020 ◽  
Vol 7 (4) ◽  
pp. 365
Author(s):  
Rais Firdaus Handoko ◽  
Budi Santosa
Keyword(s):  
Capital Market ◽  
Virus Disease ◽  
Secondary Data ◽  
Data Types ◽  
Corona Virus ◽  
Library Research ◽  
The Law ◽  
Notary Public ◽  
Novel Coronavirus ◽  
Article 5

In early 2020, the world was shocked by the rapid spread of the novel coronavirus disease known as the corona virus disease which came out at the end of 2019 (COVID-19), so that the whole world took many policies with online system, including lectures and notary activities. The purpose of this paper is to explain controversy over the principle of lex specialis derogate legi generalis in the capital market notary and legality of making the deed of the minutes of the GMS online by a capital market notary can provide justice for notaries. This research used a normative juridical research with the specification of the research was carried out descriptively and analytically. Normative research uses secondary data types. The data collection method used by conducting Library Research and the techniques used in describing and processing the collected data are qualitative descriptions. This writing can be concluded that the deed of the minutes of the GMS of capital market companies in accordance with Article 5 paragraph (1) of the Electronic Information and Transaction Law includes the so-called electronic documents which are valid evidence, while in Article 16 letter m of the Law on Notary Position, it is stated in the explanation of this Article. "That the notary must be physically present and sign the deed before the audience and witnesses". The author's suggestion is to revise the Law on the Position of Notary Public, legalize the formation of GMS minutes online both during the corona virus pandemic and after the end of the virus, so that these rules can adapt to the needs of today's life which are completely electronic, internet, digitization, and computerized.

scholarly journals COVID-19: Diagnosis, Management and Response

2021 ◽  
pp. 161-170
Author(s):  
Ashwini Shalikrao Mhaske ◽  
Swaroopa Chakole
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Hubei Province ◽  
Positive Patient ◽  
The Novel ◽  
Wuhan City ◽  
Corona Virus ◽  
Early Reaction ◽  
Novel Coronavirus ◽  
Predetermined Number

Background: COVID infection 2019 (COVID-19) is identified as a disease caused by Corona virus formally known as severe acute respiratory syndrome (SARS-CoV-2), which was first detected in Wuhan City, Hubei Province, China, amidst of an outbreak of respiratory sickness cases. Summary: As there is no affirmed total course of treatment for the Novel Coronavirus, the best way to handle it is by playing it safe, its administration and early reaction. Segregation and disinfection go inseparably with regards to dealing with a COVID positive patient. In any case, the predetermined number of clinical office accessible is blocking the cycle of control and anticipation for a particularly number of infected patients. Conclusion: As the pandemic is advancing, more examinations and exploration is needed to effectively deal with the spread of the novel Corona virus. Foundation improvement and arrangement of clinical office and gear is the preeminent prerequisite for early reaction and treatment.

scholarly journals Prevalence and risks of severe events for cancer patients with COVID-19 infection: a systematic review and meta-analysis

2020 ◽  
Author(s):  
Qiang Su ◽  
Jie-xuan Hu ◽  
Hai-shan Lin ◽  
Zheng Zhang ◽  
Emily C. Zhu ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Virus Disease ◽  
Meta Analysis ◽  
Corona Virus ◽  
Total Prevalence ◽  
Number Of Patients ◽  
Foundation Program ◽  
Novel Coronavirus ◽  
Epidemiological Characteristics ◽  
Prevalence Of Cancer

SummaryBackgroundThe corona virus disease 2019 (COVID-19) pandemic poses a severe challenge to public health, especially to those patients with underlying diseases. In this meta-analysis, we studied the prevalence of cancer among patients with COVID-19 infection and their risks of severe events.MethodsWe searched the Pubmed, Embase and MedRxiv databases for studies between December 2019 and May 3, 2020 using the following key words and terms: sars-cov-2, covid-19, 2019-ncov, 2019 novel coronavirus, corona virus disease-2019, clinical, clinical characteristics, clinical course, epidemiologic features, epidemiology, and epidemiological characteristics. We extracted data following PICO (patient, intervention, comparison and outcome) chart. Statistical analyses were performed with R Studio (version 3.5.1) on the group-level data. We assessed the studies’ risk of bias in accordance to the adjusted Joanna Briggs Institute. We estimated the prevalence or risks for severe events including admission into intensive care unit or death using meta-analysis with random effects.FindingsOut of the 2,551 studies identified, 32 studies comprising 21,248 participants have confirmed COVID-19. The total prevalence of cancer in COVID-19 patients was 3.97% (95% CI, 3.08% to 5.12%), higher than that of the total cancer rate (0.29%) in China. Stratification analysis showed that the overall cancer prevalence of COVID-19 patients in China was 2.59% (95% CI, 1.72% to 3.90%), and the prevalence reached 3.79% in Wuhan (95% CI, 2.51% to 5.70%) and 2.31% (95% CI, 1.16% to 4.57%) in other areas outside Wuhan in China. The incidence of ICU admission in cancer patients with COVID-19 was 26.80% (95% CI, 21.65% to 32.67%) and the mortality was 24.32% (95% CI, 13.95% to 38.91%), much higher than the overall rates of COVID-19 patients in China. The fatality in COVID patients with cancer was lower than those with cardiovascular disease (OR 0.49; 95% CI, 0.34 to 0.71; p=0.39), but comparable with other comorbidities such as diabetes (OR 1.32; 95% CI, 0.42 to 4.11; p=0.19), hypertension (OR 1.27; 95% CI, 0.35 to 4.62; p=0.13), and respiratory diseases (OR 0.79; 95% CI, 0.47 to 1.33; p=0.45).InterpretationThis comprehensive meta-analysis on the largest number of patients to date provides solid evidence that COVID-19 infection significantly and negatively affected the disease course and prognosis of cancer patients. Awareness of this could help guide clinicians and health policy makers in combating cancer in the context of COVID-19 pandemic.FundingBeijing Natural Science Foundation Program and Scientific Research Key Program of Beijing Municipal Commission of Education (KZ202010025047).

Sign in / Sign up

Export Citation Format

Share Document